Antiadhesion effects of docosahexaenoic acid on normal human peritoneal and adhesion fibroblasts.
OBJECTIVE
To determine whether docosahexaenoic acid (DHA) reduces adhesion marker mRNA levels in normal peritoneal and adhesion fibroblasts.


METHODS
Prospective experimental study.


METHODS
University Medical Center.


METHODS
Three patients undergoing laparotomy with excision of adhesions and normal peritoneum.


METHODS
DHA treatment (100 muM) of cell cultures for 24 hours.


METHODS
Real-time reverse transcriptase polymerase chain reaction (RT-PCR) quantification of relative changes (mRNA copies/mug mRNA) in mRNA levels of type I collagen, vascular endothelial growth factor (VEGF), and transforming growth factor-beta1 (TGF-beta1).


RESULTS
The DHA treatment significantly reduced type I collagen and VEGF, but not TGF-beta1 mRNA levels in normal peritoneal fibroblasts compared to normal controls. The DHA treatment of adhesion fibroblasts reduced type I collagen mRNAs to those of normal peritoneal fibroblasts, decreasing mRNAs by 35% compared to untreated adhesion fibroblasts. The VEGF mRNA levels were 50% lower in DHA-treated adhesion fibroblasts versus untreated adhesion fibroblasts. Docasahexaenoic acid reduced TGF- beta1 mRNA to normal levels in treated adhesion fibroblasts compared to untreated normal peritoneal fibroblasts.


CONCLUSIONS
Docasahexaenoic acid substantially reduces levels of adhesion-related markers in normal peritoneal and adhesion fibroblasts. This study provides the molecular basis for an easily administered and potentially, highly efficacious, antiadhesion adjuvant.
Victory
Rahi
R
Department of Obstetrics and Gynecology, C.S. Mott Center, Wayne State University, Detroit, Michigan 48201, USA. rahivictory@yahoo.com
Saed
Ghassan M
GM
Diamond
Michael P
MP
D002448:Cell Adhesion / Q000187:drug effects; D002478:Cells, Cultured; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism; D004281:Docosahexaenoic Acids / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D005347:Fibroblasts / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D010537:Peritoneum / Q000187:drug effects* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D000267:Tissue Adhesions / Q000235:genetics / Q000473:pathology*; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism
D024042:Collagen Type I; D012333:RNA, Messenger; D053773:Transforming Growth Factor beta1; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D004281:Docosahexaenoic Acids